Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 9.7% – Time to Buy?

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) were up 9.7% during mid-day trading on Tuesday. The stock traded as high as $14.43 and last traded at $14.37. 1,495,421 shares traded hands during trading, a decline of 13% from the average session volume of 1,725,033 shares. The stock had previously closed at $13.10.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Strong commercial growth: Third-quarter revenue rose 82% year over year to $83.3 million, exceeding expectations. Revuforj revenue increased 90% to $60.7 million, supported by 20% sequential growth in new patients, while Niktimvo generated $67.4 million in net revenue and $22.6 million in collaboration revenue. Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Potential catalysts ahead: Syndax expects additional revumenib clinical-trial and real-world data in the fourth quarter, covering multiple acute leukemia subtypes and treatment settings. Management also highlighted a higher Niktimvo margin outlook, which could improve the commercial story. Syndax Misses On EPS But Revuforj Rebound And Higher Niktimvo Margin Guide Sharpen The Commercial Story
• Positive Sentiment: External validation: Revuforj’s award win has strengthened investor enthusiasm around the drug’s commercial and competitive positioning. Brokerages maintain a consensus price target of $41.80, substantially above the current trading level. Syndax Consensus Price Target
• Neutral Sentiment: CFO transition: Aaron A. Ondrey will become CFO on November 9. Current CFO Keith Goldan is retiring but will remain through year-end to support an orderly transition, reducing the risk of an immediate disruption. Syndax Announces CFO Transition
• Negative Sentiment: Profitability remains pressured: Syndax reported a third-quarter loss of $0.55 per share, missing consensus estimates near $0.49–$0.52, although the loss improved from $0.70 a year earlier. Analysts continue to expect a full-year loss, and commentary cited pipeline setbacks that could limit the stock’s upside.
• Negative Sentiment: Valuation risk: One analysis argues that SNDX may already be richly valued after the Revuforj award, suggesting that strong execution and upcoming data may be needed to justify further gains. Syndax Stock May Be Rich After Revuforj Award Win

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on SNDX shares. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. UBS Group reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Mizuho set a $43.00 price target on Syndax Pharmaceuticals in a report on Tuesday. Weiss Ratings lowered Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Finally, HC Wainwright reduced their price target on Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.60.

Syndax Pharmaceuticals Trading Up 9.3%

The company has a 50 day moving average of $17.05 and a two-hundred day moving average of $20.21. The stock has a market capitalization of $1.27 billion, a PE ratio of -5.71 and a beta of 0.42. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 6.77.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The business had revenue of $83.30 million during the quarter, compared to analysts’ expectations of $81.80 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The company’s quarterly revenue was up 81.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.70) earnings per share. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Insider Buying and Selling

In other news, Director Dennis Podlesak sold 8,000 shares of the stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the transaction, the director directly owned 239,763 shares of the company’s stock, valued at approximately $3,407,032.23. This represents a 3.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in SNDX. Arizona State Retirement System grew its position in Syndax Pharmaceuticals by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 23,120 shares of the company’s stock worth $505,000 after purchasing an additional 642 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Syndax Pharmaceuticals by 0.5% in the 2nd quarter. Wellington Management Group LLP now owns 124,241 shares of the company’s stock valued at $2,716,000 after buying an additional 655 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Syndax Pharmaceuticals by 3.2% in the first quarter. Hsbc Holdings PLC now owns 23,461 shares of the company’s stock worth $556,000 after buying an additional 730 shares during the last quarter. Allworth Financial LP purchased a new stake in Syndax Pharmaceuticals in the 2nd quarter worth approximately $26,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Syndax Pharmaceuticals by 11.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,564 shares of the company’s stock worth $467,000 after acquiring an additional 2,002 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.